Flavokawain A

Flavokawain A at a Glance

Flavokawain A is a chalcone — a small, open-chain flavonoid-type molecule — and one of the three “flavokawains” (A, B and C) that give kava (Piper methysticum) its faint yellow pigment. It is the most abundant of the triad, but still a minor constituent of the plant: the kavalactones, not the chalcones, are what dominate the root and carry kava’s traditional anxiolytic effect.

What makes flavokawain A interesting is that it points in two directions at once. In the laboratory it is a pro-apoptotic anticancer chalcone, best characterised in bladder cancer, where it triggers mitochondrial (Bax-dependent) cell death and suppresses tumour growth in mice ^{1Reference 1Zi X · 2005AnimalFlavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in miceView study →}; more recent work identifies it as a natural PRMT5 inhibitor ^{2Reference 2Liu S et al. · 2022Flavokawain A is a natural inhibitor of PRMT5 in bladder cancerView study →}. At the same time, it is one of the constituents caught up in the long-running question of kava-associated liver injury — in mice, flavokawains A and B (but not the kavalactone dihydromethysticin) potentiate acetaminophen hepatotoxicity ^{9Reference 9Narayanapillai SC et al. · 2014AnimalFlavokawains A and B in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 miceView study →}.

The honest headline is that all of this is preclinical. There are no human efficacy trials of isolated flavokawain A, and its role in real-world kava safety is a hypothesis about plant part and chemotype, not a settled verdict.

A Chalcone With Two Faces

Flavokawain A’s signature is that the same molecule anchors both an optimistic anticancer story and a cautionary safety one — and both are worth stating plainly because they are easy to conflate or to oversell.

The anticancer face. The molecule that put flavokawains on the map. In the founding study, flavokawain A induced apoptosis in bladder-cancer cell lines through a Bax-dependent, mitochondria-dependent pathway and suppressed tumour growth in mice, while sparing normal urothelial cells at the tested concentrations ^{1Reference 1Zi X · 2005AnimalFlavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in miceView study →}. Subsequent work broadened the picture: it reduces the tumour-initiating, stem-like properties of prostate cancer cells ^{3Reference 3Song L et al. · 2022Flavokawain A reduces tumor-initiating properties and stemness of prostate cancerView study →}, suppresses vasculogenic mimicry in hepatocellular carcinoma by acting on the CXCL12/CXCR4 axis and EMT ^{4Reference 4Xiao T et al. · 2023Flavokawain A suppresses the vasculogenic mimicry of HCC by inhibiting CXCL12 mediated EMTView study →}, and was re-cast in 2022 as a natural PRMT5 inhibitor in bladder cancer — a defined molecular target rather than a vague “chalcone effect” ^{2Reference 2Liu S et al. · 2022Flavokawain A is a natural inhibitor of PRMT5 in bladder cancerView study →}. A dedicated review calls the flavokawains “uprising medicinal chalcones” for exactly this reason ^{5Reference 5Abu N et al. · 2013The flavokawains: uprising medicinal chalconesView study →}.

The hepatotoxicity face. The flip side is that flavokawain A is one of the constituents named in the kava hepatotoxicity debate. The pivotal mouse experiment showed that flavokawains A and B — not the kavalactone dihydromethysticin — potentiate acetaminophen (APAP) liver injury ^{9Reference 9Narayanapillai SC et al. · 2014AnimalFlavokawains A and B in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 miceView study →}, and reviews of kava-associated hepatotoxicity repeatedly list the flavokawains (especially flavokawain B) among the candidate culprits ^{10Reference 10Teschke R et al. · 2011Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culpritsView study →}. Flavokawain A is the more abundant and better-studied member, so it inherits part of that suspicion even though its sibling flavokawain B is usually cast as the more directly hepatotoxic one.

The tension is more apparent than real: a molecule that pushes stressed or cancerous cells toward apoptosis can be exactly the kind of molecule that becomes a liability for hepatocytes under a second chemical stress (like an APAP overdose). Pro-apoptotic in a tumour is protective; pro-apoptotic in an overloaded liver is not.

The Kava Hepatotoxicity Question

Kava was pulled from several markets in the early 2000s after reports of rare but serious liver injury, and untangling why has occupied the field ever since. Flavokawain A sits inside that question, and the useful framing for a molecule page is which part of the plant, and which chemotype, the risk tracks to.

• The root kavalactones look comparatively safe. Traditional kava is a water extract of peeled root, and the six major kavalactones that carry ~96% of kava’s activity are not the constituents that flag in the hepatotoxicity work ^{9Reference 9Narayanapillai SC et al. · 2014AnimalFlavokawains A and B in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 miceView study →}.
• The suspicion falls on non-root, non-kavalactone material. Two candidate stories overlap: the piperidine alkaloid pipermethystine, concentrated in leaves and stem peelings rather than root, is cytotoxic to human HepG2 hepatocytes in vitro ^{11Reference 11Nerurkar PV et al. · 2004In vitroIn vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactonesView study →}; and the flavokawain chalcones, which run higher in aerial parts and in two-day (tudei) chemotypes, potentiate chemical liver injury in mice ^{9,10Reference 9Narayanapillai SC et al. · 2014AnimalFlavokawains A and B in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 miceView study →Reference 10Teschke R et al. · 2011Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culpritsView study →}.
• Flavokawain A’s specific role is a potentiator, not a proven stand-alone hepatotoxin. The strongest direct evidence is that it amplifies APAP toxicity in mice ^{9Reference 9Narayanapillai SC et al. · 2014AnimalFlavokawains A and B in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 miceView study →}; whether ordinary root-based kava delivers enough flavokawain A to matter in humans is unresolved.

The practical read: this is a plant-part and chemotype problem, and flavokawain A is one thread in it — a reason to favour peeled-root, noble-cultivar, aqueous kava, not a reason to treat the isolated chalcone as a proven human hepatotoxin.

What It's Used For

Flavokawain A’s pharmacology is entirely preclinical — cell lines and rodents, testing the isolated molecule. The evidence is strongest and most coherent in oncology; the newer anti-fibrotic and gynaecological signals are single-study and early.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Every application here is preclinical isolate data, so scores stay modest by design and the anticancer row leads only because it has the most independent studies and a defined target.

01Anticancer / pro-apoptoticShaky42%Multiple cell lines + mouse xenograft; Bax/mitochondrial apoptosis; PRMT5 target ^{1,2,3,4,5Reference 1Zi X · 2005AnimalFlavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in miceView study →Reference 2Liu S et al. · 2022Flavokawain A is a natural inhibitor of PRMT5 in bladder cancerView study →Reference 3Song L et al. · 2022Flavokawain A reduces tumor-initiating properties and stemness of prostate cancerView study →Reference 4Xiao T et al. · 2023Flavokawain A suppresses the vasculogenic mimicry of HCC by inhibiting CXCL12 mediated EMTView study →Reference 5Abu N et al. · 2013The flavokawains: uprising medicinal chalconesView study →}

02Anti-fibrotic / tissue-protectiveShaky26%Single-study rodent/in-vitro: pulmonary fibrosis (TGF-β), osteoarthritis ^{6,7Reference 6Xiao T et al. · 2023Flavokawain A ameliorates pulmonary fibrosis by inhibiting the TGF-β signaling pathway and CXCL12/CXCR4 axisView study →Reference 7Jing S et al. · 2022In vitroFlavokawain A alleviates the progression of mouse osteoarthritis: an in vitro and in vivo studyView study →}

03Endometriosis (hormone-driven)Shaky18%One surgically-induced rat model ^{8Reference 8Wei Z et al. · 2024AnimalBeneficial biological effects of flavokawain A, a chalcone constituent from kava, on a surgically induced endometriosis rat modelView study →}

Mechanisms

The load-bearing point is that the pro-apoptotic mitochondrial action that makes flavokawain A attractive against tumour cells is the same kind of action that plausibly makes it a liability for stressed hepatocytes ^{1,9Reference 1Zi X · 2005AnimalFlavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in miceView study →Reference 9Narayanapillai SC et al. · 2014AnimalFlavokawains A and B in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 miceView study →}.

Pharmacokinetics

Flavokawain A’s human pharmacokinetics are essentially uncharacterised — a real limitation for interpreting the in-vitro potency. As a lipophilic chalcone with low aqueous solubility, poor oral absorption and rapid metabolism are the expected pattern for this chemotype, but no reliable human Cmax, half-life or oral-bioavailability figures are established. This matters twice over: it means the anticancer concentrations used in cell culture may not be reachable in a person, and it means the exposure delivered by ordinary kava products is unknown. Analytical characterisation of kava products (UPLC-MS/MS, supercritical-fluid extracts) confirms flavokawain A is present but at low levels relative to the kavalactones, varying with product form and chemotype ^{12,13Reference 12Mamallapalli J et al. · 2022Characterization of different forms of kava (Piper methysticum) products by UPLC-MS/MSView study →Reference 13Petersen GE et al. · 2019In vitroChemical and in vitro toxicity analysis of a supercritical fluid extract of kava kava (Piper methysticum)View study →}.

Clinical Trials

There are no clinical trials of isolated flavokawain A for any indication. The entire evidence base is preclinical; the only human exposure is incidental, as a minor chalcone within kava products.

Last checked: July 2026.

Isolate vs. Plant Studies

Flavokawain A is a case where the isolate is almost the whole story — but that is not the strength it would be for a molecule with human data. Every pharmacology finding above tests the purified chalcone in cell lines or rodents ^{1,2,3,4Reference 1Zi X · 2005AnimalFlavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in miceView study →Reference 2Liu S et al. · 2022Flavokawain A is a natural inhibitor of PRMT5 in bladder cancerView study →Reference 3Song L et al. · 2022Flavokawain A reduces tumor-initiating properties and stemness of prostate cancerView study →Reference 4Xiao T et al. · 2023Flavokawain A suppresses the vasculogenic mimicry of HCC by inhibiting CXCL12 mediated EMTView study →}, so there is no isolate-versus-extract discrepancy to reconcile on the efficacy side; there is simply no human efficacy evidence at either level.

Where the plant context reasserts itself is safety. In real kava, flavokawain A is a minor constituent embedded in a matrix dominated by kavalactones ^{12,13Reference 12Mamallapalli J et al. · 2022Characterization of different forms of kava (Piper methysticum) products by UPLC-MS/MSView study →Reference 13Petersen GE et al. · 2019In vitroChemical and in vitro toxicity analysis of a supercritical fluid extract of kava kava (Piper methysticum)View study →}, and its implicated harm — potentiating chemical liver injury — was itself demonstrated with the isolated chalcones in mice ^{9Reference 9Narayanapillai SC et al. · 2014AnimalFlavokawains A and B in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 miceView study →}. So the isolate work cuts both ways: it is the basis of the anticancer optimism and of the hepatotoxicity suspicion, while the question that actually governs human risk — how much flavokawain A a given kava product delivers — is a plant-part and chemotype question the isolate studies cannot answer.

Prevalence in Nature

Flavokawain A is characteristically a kava chalcone: it takes its name from kawa (kava) and is one of three flavokawains (A, B, C) that co-occur in Piper methysticum. Among the triad it is the most abundant, though the flavokawains together are minor pigments beside the kavalactones that make up the bulk of the resin ^{12Reference 12Mamallapalli J et al. · 2022Characterization of different forms of kava (Piper methysticum) products by UPLC-MS/MSView study →}.

Its distribution within the plant is the safety-relevant part: flavokawain content is reported to be higher in the aerial parts (leaves, stem peelings) and in two-day (tudei) and wichmannii chemotypes than in peeled noble root — the same plant-part/chemotype gradient that runs through the hepatotoxicity discussion ^{10,13Reference 10Teschke R et al. · 2011Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culpritsView study →Reference 13Petersen GE et al. · 2019In vitroChemical and in vitro toxicity analysis of a supercritical fluid extract of kava kava (Piper methysticum)View study →}. Beyond kava, flavokawain A has been reported as a minor constituent of a few other species (some Alpinia), but it is not a widespread plant compound in the way monoterpenes or common flavonols are — it is, for practical purposes, a kava marker chalcone.

Discovery & Synthesis

Flavokawain A entered the modern literature through kava chemistry: it was isolated as one of the “flavokawains” (also spelled flavokavains), the yellow chalcone pigments of Piper methysticum, and its name encodes that origin (flavo-, yellow; -kawain, from kava). Its scientific prominence dates to the 2005 study by Xianghong Zi and Anne Simoneau, which characterised it as a novel anticancer chalcone from kava extract and demonstrated the Bax/mitochondrial apoptosis mechanism and mouse tumour suppression that every later oncology paper builds on ^{1Reference 1Zi X · 2005AnimalFlavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in miceView study →}.

As a simple 2’-hydroxychalcone, flavokawain A is synthetically accessible by the classic route to chalcones — a Claisen–Schmidt aldol condensation between an acetophenone and a benzaldehyde bearing the appropriate methoxy/hydroxy substitution — which is how research quantities are typically prepared rather than extracted from kava. A full, well-documented account of its first total synthesis and of any dominant commercial route is not established in the sources reviewed here; for research it is available both as a kava-extract isolate and as a synthesised chalcone.

Patents: not yet researched.

Toxicity & Safety

Flavokawain A carries a moderate flag — above a typical dietary flavonoid — for one specific, evidenced reason: in mice it potentiates acetaminophen-induced liver injury, and it is one of the chalcones named in the kava-associated hepatotoxicity literature ^{9,10Reference 9Narayanapillai SC et al. · 2014AnimalFlavokawains A and B in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 miceView study →Reference 10Teschke R et al. · 2011Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culpritsView study →}. This is a genuine signal, but it must be read with two caveats: it is animal data on the isolated chalcone, and flavokawain A’s exposure from ordinary root-based kava is low and uncharacterised.

Safety at a Glance

⚠️ Moderate toxicityDrug interactions

• Not the actor in traditional kava’s benefit — or, on current evidence, a proven stand-alone human hepatotoxin. It is a minor chalcone; the intended actives in kava are the root kavalactones.
• Hepatotoxicity signal. In mice, flavokawains A and B (not the kavalactone dihydromethysticin) potentiate acetaminophen liver injury; the flavokawains are recurring suspects in kava-associated hepatotoxicity ^{9,10Reference 9Narayanapillai SC et al. · 2014AnimalFlavokawains A and B in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 miceView study →Reference 10Teschke R et al. · 2011Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culpritsView study →}.
• Plant part and chemotype matter. Flavokawain load runs higher in aerial parts and in two-day (tudei) chemotypes than in peeled noble root — favour peeled-root, noble, aqueous kava ^{10,13Reference 10Teschke R et al. · 2011Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culpritsView study →Reference 13Petersen GE et al. · 2019In vitroChemical and in vitro toxicity analysis of a supercritical fluid extract of kava kava (Piper methysticum)View study →}.
• Additive-stress interaction, in principle. A pro-apoptotic molecule that amplifies APAP toxicity in mice warrants caution about combining kava (especially non-noble/aerial-part products) with hepatic stressors such as acetaminophen or alcohol ^{9Reference 9Narayanapillai SC et al. · 2014AnimalFlavokawains A and B in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 miceView study →}.
• No human safety data on the isolate, and its pharmacokinetics are uncharacterised — absence of evidence is not evidence of safety.

Reproductive and developmental toxicity data for isolated flavokawain A are not established. Pregnancy and lactation decisions belong to the kava herb or product page where intake is actually decided, not to this molecule page; no isolate-specific verdict is issued here.

Dosage

There is no established or recommended human dose for isolated flavokawain A. Every figure in the research literature is a preclinical cell-culture concentration or a rodent research dose — used to demonstrate mechanism, not to guide human intake — and none is convertible to a self-dose, especially given the compound’s uncharacterised human pharmacokinetics ^{1,2Reference 1Zi X · 2005AnimalFlavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in miceView study →Reference 2Liu S et al. · 2022Flavokawain A is a natural inhibitor of PRMT5 in bladder cancerView study →}.

Human exposure is indirect and low: flavokawain A is a minor chalcone within kava products, where the intended actives are the kavalactones and the flavokawain content varies with product form, plant part and chemotype ^{12,13Reference 12Mamallapalli J et al. · 2022Characterization of different forms of kava (Piper methysticum) products by UPLC-MS/MSView study →Reference 13Petersen GE et al. · 2019In vitroChemical and in vitro toxicity analysis of a supercritical fluid extract of kava kava (Piper methysticum)View study →}. The relevant practical control is therefore not a flavokawain dose but a product choice — peeled-root, noble-cultivar, aqueous kava carries less flavokawain than aerial-part or two-day-chemotype material ^{10,13Reference 10Teschke R et al. · 2011Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culpritsView study →Reference 13Petersen GE et al. · 2019In vitroChemical and in vitro toxicity analysis of a supercritical fluid extract of kava kava (Piper methysticum)View study →}. These are research figures and product observations, not a personal recommendation.

References

1. Zi X, Simoneau AR (2005). Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice. Cancer Research. https://pubmed.ncbi.nlm.nih.gov/15833884/
2. Liu S, Liu Z, Piao C, et al. (2022). Flavokawain A is a natural inhibitor of PRMT5 in bladder cancer. Journal of Experimental & Clinical Cancer Research. https://pubmed.ncbi.nlm.nih.gov/36199122/
3. Song L, Mino M, Yamak J, et al. (2022). Flavokawain A reduces tumor-initiating properties and stemness of prostate cancer. Frontiers in Oncology. https://pubmed.ncbi.nlm.nih.gov/35912174/
4. Xiao T, Bao J, Tian J, et al. (2023). Flavokawain A suppresses the vasculogenic mimicry of HCC by inhibiting CXCL12 mediated EMT. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/36804756/
5. Abu N, Ho WY, Yeap SK, et al. (2013). The flavokawains: uprising medicinal chalcones. Cancer Cell International. https://pubmed.ncbi.nlm.nih.gov/24148263/
6. Xiao T, Gao D, et al. (2023). Flavokawain A ameliorates pulmonary fibrosis by inhibiting the TGF-β signaling pathway and CXCL12/CXCR4 axis. European Journal of Pharmacology. https://pubmed.ncbi.nlm.nih.gov/37579968/
7. Jing S, Wan J, et al. (2022). Flavokawain A alleviates the progression of mouse osteoarthritis: an in vitro and in vivo study. Frontiers in Bioengineering and Biotechnology. https://pubmed.ncbi.nlm.nih.gov/36545678/
8. Wei Z, Gu X, et al. (2024). Beneficial biological effects of flavokawain A, a chalcone constituent from kava, on a surgically induced endometriosis rat model. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/37437790/
9. Narayanapillai SC, Leitzman P, O’Sullivan MG, et al. (2014). Flavokawains A and B in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 mice. Chemical Research in Toxicology. https://pubmed.ncbi.nlm.nih.gov/25185080/
10. Teschke R, Qiu SX, Lebot V (2011). Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culprits. Digestive and Liver Disease. https://pubmed.ncbi.nlm.nih.gov/21377431/
11. Nerurkar PV, Dragull K, Tang CS (2004). In vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactones. Toxicological Sciences. https://pubmed.ncbi.nlm.nih.gov/14737001/
12. Mamallapalli J, Kanumuri SRR, Corral P, et al. (2022). Characterization of different forms of kava (Piper methysticum) products by UPLC-MS/MS. Planta Medica. https://pubmed.ncbi.nlm.nih.gov/34839465/
13. Petersen GE, Tang Y, Fields C (2019). Chemical and in vitro toxicity analysis of a supercritical fluid extract of kava kava (Piper methysticum). Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/30710733/

View all 13 references▾